According to Zhitong Finance App, Gloria Ying (002821.SZ) released its report for the third quarter of 2026. The company achieved operating income of 5.395 billion yuan in the first three quarters, up 16.52% year on year; net profit attributable to shareholders of listed companies was 852 million yuan, up 6.49% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 728 million yuan, up 0.04% year on year; basic earnings per share were 2.36 yuan.

Currently, the CDMO industry has shown a positive trend. The company grasps the changing trends in the innovative drug industry and continues to increase market development, capacity building and production capacity investment, especially in incremental business sectors such as peptides, oligonucleotides, and ADC, laying a solid foundation for continued steady growth in performance. During the reporting period, the company maintained double-digit year-on-year growth in new orders. Post-clinical or commercial projects in the CDMO industry have characteristics such as large supply volume, long execution cycle, and strong planning. Corresponding orders are usually delivered centrally in the second half of the year. Judging from the company's pending delivery orders, the delivery scale in the fourth quarter will increase significantly compared to the current period, and the company expects revenue to increase 19%-22% for the full year of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.